학술논문
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
Document Type
Article
Author
Livingstone, E.; Gogas, H.; Kandolf-Sekulovic, L.; Meier, F.; Eigentler, T.K.; Ziemer, M.; Terheyden, P.A.M.; Gesierich, A.H.; Herbst, R.A.; Kähler, K.C.; Ziogas, D.C.; Mijuskovic, Z.; Garzarolli, M.; Garbe, C.; Roesch, A.; Ugurel, S.; Gutzmer, R.; Grob, J.J.; Kiecker, F.; Utikal, J.; Windemuth-Kieselbach, C.; Eckhardt, S.; Zimmer, L.; Schadendorf, D.
Source
In European Journal of Cancer September 2023 190
Subject
Language
ISSN
0959-8049